Topics
-
Key Inflation Report Looms After Powell Doubles Down on Future Rate Hikes
|Federal Reserve chairperson Jerome Powell appeared before Congress on March 6 and indicated that rates may have to increase more than expected in 2023 to tame persistently high inflation -
New 200% Aluminum Tariff Designed to Punish Russia
|Trading volumes surged in the aluminum futures market after the U.S. unveiled fresh tariffs on Russian aluminum exports -
What You Need to Know About Trading ‘Zero-day’ Options
|Options with zero days until expiration only exist for a single trading session, and recent market data suggests that trading volume in these Zero-day, or 0DTE, contracts has been surging… -
The Myth of Drug Expiration Dates
By Nav Dhillon
|There’s not necessarily anything scientific or magical about the dates printed on medications Those expiration dates stamped on everything from a gallon of milk to a bottle of acetaminophen don’t… -
Luckbox Leans in with Mark Cuban
By James Melton
|Cost Plus Drugs Company is selling prescription medications at dramatically low prices What would happen if drug pricing made sense to consumers? Mark Cuban Cost Plus Drug Company, which launched… -
ADHD Meds? You May Have to Wait
By James Melton
|A shortage began with Adderall and spread to Ritalin. A government crackdown made it worse. As 2023 began, the national Adderall shortage had spread to other drugs used to treat… -
Betting on Biotech
|Active investors can navigate the boom or bust biotech sector with the help of strategies like C-suite buying, cash to value and cash flow Sick people need medicine no matter… -
The First $100 Billion Drug
By Ed McKinley
|An obesity medication is reportedly poised to shatter the record for pharmaceutical sales volume A prescription drug that combats obesity is expected to become the biggest-grossing pharmaceutical in history, ringing… -
Off-label, But Lucrative
By Nav Dhillon
|Big pharma profits when doctors prescribe a drug for a disorder other than the one that earned FDA approval. The practice ranges from evidence-based to highly egregious. One in five… -
Competition Coming for AbbVie’s Blockbuster
|It’s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats Worldwide sales of Humira have totaled $200 billion in the last 20 years—just about the biggest haul…